Navigation Links
Loss of gene promotes brain-tumor development, reduces survival, study finds
Date:1/6/2011

COLUMBUS, Ohio New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

The study was published recently in the New England Journal of Medicine.

"We show that NFKBIA status may be an independent predictor of survival in certain patients with glioblastoma," says senior coauthor Dr. Arnab Chakravarti, chair and professor of Radiation Oncology and co-director of the Brain Tumor Program at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

"We also show that this gene plays a key role in glioblastoma behavior, and that it could be useful for predicting treatment outcomes," he says.

An estimated 18, 500 new cases of glioblastoma occur annually among Americans, resulting in 12,760 deaths. Average survival after diagnosis is about 12 to 15 months.

Most cases of the disease are driven by over activity of a gene called EGFR (epidermal growth factor receptor). This study shows that loss of NFKBIA (nuclear factor of kappa-light polypeptide gene enhancer in B-cells inhibitor-alpha) and overexpression EGFR are equally potent at driving glioblastoma development.

It also shows that glioblastoma tumors generally show either abnormally high levels of EGFR or loss of NFKBIA, but not both. Normal levels of both genes also occur.

Chakravarti, along with Markus Bredel, an adjunct associate professor of radiation oncology at Ohio State and their colleagues analyzed data from 790 cases of glioblastoma, which they divided into 10 study sets, for gene deletions, mutations, and expression of NFKBIA and EGFR.

Using glioblastoma cell lines and tumor cells from patients, they examined the influence of the NFKBIA gene on tumor-cell growth and sensitivity to temozolomide, the most effective chemotherapy for glioblastoma. Finally, they compared these findings with the outcomes of 570 glioblastoma patients.

These investigations showed the following:

  • Restoring NFKBIA in tumor cells inhibited their growth and viability and increased the cells' sensitivity to temozolomide.
  • Restoring NFKBIA suppresses the growth of glioblastoma cells that are driven by overexpression of EGFR.
  • Patients with both copies of NFKBIA survive significantly longer than did patients with tumors that have lost a copy of the gene (131 weeks and 57 weeks, respectively).


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Father Channels His Grief into Advocacy, Promotes Simple Actions to Make Hospitals Safer for Children
2. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
3. Medical Transcription Services and EHR Provider MxSecure Promotes Tim Erkel to VP, Client Services
4. Hearts and Minds Promotes Wellness; African Americans Living with Mental Illness Have Higher Risk for Other Illnesses.
5. Pinstripe Promotes Jill Schwieters to President of Pinstripe Healthcare
6. Scientific exchange program promotes collaborative quality standards for drugs, food ingredients
7. Scientists find key to gene that promotes cancer metastasis
8. Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives
9. Brain Health Expert Says OASIS Promotes Brain Fitness
10. New Anti-Aging Skin Care Line Promotes Penetration
11. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... New Brunswick, New Jersey: This year marks Children’s Specialized Hospital ’s 125th ... the anniversary, the hospital has themed the milestone “Hats Off” and kicked off the ... on Saturday, May 21, at Johnson Park in Piscataway, New Jersey. , ...
(Date:5/24/2016)... — , ... (PRWEB) ... of three new members of its Advisory Board. Joining the ... Sarah Kusch. “All three of them embody the mission of our ... are very fortunate to have them as we continue to expand ...
(Date:5/24/2016)... ... ... Boyd Industries, a leading supplier of dental chairs and cabinetry , will ... dentistry , at AAPD 2016, the annual conference and trade show of the American ... keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery system out ...
(Date:5/24/2016)... Angeles, CA (PRWEB) , ... May 24, 2016 ... ... to everything egg freezing, today announced the official relaunch of its community and ... use their frozen eggs. Eggsurance's mission is to create a safe and welcoming ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 ... titled, " Exocrine Pancreatic Insufficiency Market - Global Industry ... 2023 ." According to the report, the exocrine pancreatic ... of 8.3% from 2015 to 2023 to reach US$2.85 ... is a condition characterized by the deficiency of the ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
Breaking Medicine Technology: